Clinical Trials Logo
NCT number NCT03186703
Study type Interventional
Source McMaster University
Contact Sarah Neil-Sztramko, PhD
Phone 905-525-9140
Email neilszts@mcmaster.ca
Status Not yet recruiting
Phase N/A
Start date August 1, 2017
Completion date March 31, 2018

Clinical Trial Summary

The goal of the McMaster Optimal Aging Portal is to be a trustworthy source for health information. The Portal team can see (through measuring analytics of website use) that thousands of people are using the Portal and the knowledge-sharing strategies in place (email alerts, Twitter and Facebook), with many more users added each month. Previous studies have measured the quality and trustworthiness of health information available online; others have studied the numbers and populations who use different types of information and how easy it is to use and understand. This study builds on that knowledge to find out: if easy-to-understand evidence-based messages reach members of the public, do these messages change what people know and think to do to stay healthy (in this case, what they know and think to do to lower their risk of cancer)?


Clinical Trial Description

Half of cancers are preventable through lifestyle modification such as smoking cessation, healthy eating, increasing physical activity and reducing alcohol intake; however, few Canadians engage in behaviours that are in line with cancer prevention guidelines. This may be in part due to lack of access to evidence-based information and the mixed messages on effective cancer prevention strategies that are propagated in the popular media.

The McMaster Optimal Aging Portal (the Portal) is a knowledge translation (KT) tool launched in 2014 to increase public access to trustworthy health information. Citizen-friendly content (blog posts, evidence summaries, web resource ratings) provide easy-to-read 'bottom line' messages appropriate for all audiences. Investigators would now like to know if and how KT strategies used to disseminate citizen-targeted information on cancer prevention impact knowledge, behavioural intentions and health behaviours of Canadian adults.

This study will use a sequential mixed-methods design consisting of a two-arm randomized controlled trial (RCT) and a qualitative process study to explore RCT findings in depth. This formative approach will allow for a deeper analysis of the outcomes of interest (knowledge, intentions and behaviours), and the KT process. Following baseline data collection, eligible participants will be randomized to a 12-week intervention or control group.

During the intervention, participants will have access to the Portal, be invited to follow a Twitter and Facebook feed, and receive tailored weekly email alerts including blog posts and evidence summaries on cancer prevention. Control group participants will have access the Portal in a 'self-serve' fashion, but will not receive KT strategies.


Study Design


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Recruiting NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
 Active, not recruiting NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
 Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development N/A
 Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
 Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness N/A
 Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer N/A
 Enrolling by invitation NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer N/A
 Recruiting NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
 Recruiting NCT02891993 - Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer N/A
 Recruiting NCT02921919 - Open-Label Extension and Safety Study of Talazoparib Phase 2
 Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis N/A
 Not yet recruiting NCT02883699 - Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study N/A
 Recruiting NCT02550925 - Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors N/A
 Recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center N/A
 Recruiting NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
 Recruiting NCT02662621 - Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors N/A
 Recruiting NCT02552953 - A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers Phase 1
 Recruiting NCT02528357 - GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1) Phase 1
 Recruiting NCT02765451 - Study Evaluating Intervention in the Development of Clinical Research in Non-Academic Health Institution (ERNU) N/A
 Recruiting NCT02483247 - A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Phase 1/Phase 2